Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020

Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020

MenB-FHBp was licensed in Europe in 2017 from the age of 10. In the “postmarketing life” of a new vaccine, surveillance of Adverse Events Following Immunization (AEFI) is crucial, to better understand the pattern of safety and the effectiveness. This paper describes the MenB-FHBp AEFIs notified in P...

Full description

Bibliographic Details
Main Authors: Pasquale Stefanizzi, Francesco Paolo Bianchi, Andrea Martinelli, Antonio Di Lorenzo, Paola De Petro, Giusi Graziano, Sabrina Lattanzio, Giusy Diella, Paolo Stella, Domenica Ancona, Silvio Tafuri
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
aefis
causality assessment
trumenba
vaccination confidence
Online Access:http://dx.doi.org/10.1080/21645515.2022.2041359

Internet

http://dx.doi.org/10.1080/21645515.2022.2041359

Similar Items